MX2021014157A - Formas cristalinas de un inhibidor btk. - Google Patents

Formas cristalinas de un inhibidor btk.

Info

Publication number
MX2021014157A
MX2021014157A MX2021014157A MX2021014157A MX2021014157A MX 2021014157 A MX2021014157 A MX 2021014157A MX 2021014157 A MX2021014157 A MX 2021014157A MX 2021014157 A MX2021014157 A MX 2021014157A MX 2021014157 A MX2021014157 A MX 2021014157A
Authority
MX
Mexico
Prior art keywords
crystalline forms
disorders
btk inhibitor
diseases
btk
Prior art date
Application number
MX2021014157A
Other languages
English (en)
Inventor
Daniela Angst
Andreas Kordikowski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021014157A publication Critical patent/MX2021014157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente solicitud se refiere a varias formas cristalinas anhidras N-(3-(6-amino-5-(2-(N-metilacrilamido)etoxi)pirimidin-4-i l)-5-fluoro-2-metilfenil)-4-ciclopropil-2-fluorobenzamida, así como composiciones, método de fabricación y sus métodos de uso. Estas formas cristalinas son útiles en el tratamiento de enfermedades y trastornos que típicamente se mejoran mediante la inhibición de BTK. Dichas enfermedades y trastornos pueden incluir trastornos inflamatorios y autoinmunes e inflamación pulmonar y del tracto respiratorio.
MX2021014157A 2019-05-23 2020-05-20 Formas cristalinas de un inhibidor btk. MX2021014157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851986P 2019-05-23 2019-05-23
PCT/IB2020/054752 WO2020234779A1 (en) 2019-05-23 2020-05-20 Crystalline forms of a btk inhibitor

Publications (1)

Publication Number Publication Date
MX2021014157A true MX2021014157A (es) 2022-01-04

Family

ID=70918748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014157A MX2021014157A (es) 2019-05-23 2020-05-20 Formas cristalinas de un inhibidor btk.

Country Status (13)

Country Link
EP (1) EP3972960A1 (es)
JP (1) JP2022534216A (es)
KR (1) KR20220012280A (es)
CN (1) CN113840821A (es)
AR (1) AR118981A1 (es)
AU (1) AU2020279927A1 (es)
BR (1) BR112021023054A2 (es)
CA (1) CA3137790A1 (es)
CL (1) CL2021003057A1 (es)
IL (1) IL287668A (es)
MX (1) MX2021014157A (es)
TW (1) TW202110811A (es)
WO (1) WO2020234779A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022033569A1 (zh) * 2020-08-14 2022-02-17 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
TW202245778A (zh) 2021-01-26 2022-12-01 瑞士商諾華公司 藥物組成物
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
JP2024504267A (ja) 2021-12-14 2024-01-31 ノバルティス アーゲー Ｌｏｕ０６４を使用した治療の方法
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
WO2024069507A1 (en) 2022-09-30 2024-04-04 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020544A1 (es) 2000-11-07 2002-07-30 Novartis Ag Derivados de indolilmaleimida
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
BR0317099A (pt) 2002-12-09 2005-10-25 Boardd Of Regents Of The Unive Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
EP3972960A1 (en) 2022-03-30
KR20220012280A (ko) 2022-02-03
IL287668A (en) 2021-12-01
CA3137790A1 (en) 2020-11-26
AU2020279927A1 (en) 2022-01-06
CL2021003057A1 (es) 2022-09-09
JP2022534216A (ja) 2022-07-28
CN113840821A (zh) 2021-12-24
AR118981A1 (es) 2021-11-17
WO2020234779A1 (en) 2020-11-26
BR112021023054A2 (pt) 2022-03-29
TW202110811A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
MX2021014157A (es) Formas cristalinas de un inhibidor btk.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
EA202090256A1 (ru) 5-членные и бициклические гетероциклические амиды в качестве ингибиторов rock
TN2019000281A1 (en) Ferroportin-inhibitor salts
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
IN2014DN09352A (es)
IN2014DN09348A (es)
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
MX367154B (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
EA201270716A1 (ru) Макроциклы в качестве ингибиторов фактора xia
CU20200084A7 (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
CR20200413A (es) Inhibidores de canal de potencial de receptor transitorio de oxadiazol
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
CR20210072A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
MX2018001204A (es) Metodo para preparar derivados de acido 3-(2-anilino-1-ciclohexil- 1h-bencimidazol-5-il)propanoico sustituido.
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
NZ738836A (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
IN2014DN09347A (es)
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2